CABA - Company ID 0001759138
The table below shows Cabaletta Bio, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.56M | -$30.80M | -$23.99M | -$12.61M | -$12.81M | -$8.67M |
| Capital expenditure | $0.00 | $785.00K | $812.00K | $380.00K | $147.00K | $97.00K |
| Investing cash flow | $50.96M | -$785.00K | -$812.00K | $24.62M | -$49.91M | $2.35M |
| Dividends paid | - | - | - |
Cabaletta Bio, Inc. reported operating cash flow of -$131.08M for fiscal year 2025. That is down 48.6% from -$88.22M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$4.66M (FY 2018) to -$131.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $25.27M | -$552.00K | $6.86M | $226.00K | $51.00K | $2.17M |